As of close of business last night, Revolution Medicines Inc’s stock clocked out at $30.80, down -0.45% from its previous closing price of $30.94. In other words, the price has decreased by -$0.14 from its previous closing price. On the day, 1166281 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
To gain a deeper understanding of RVMD’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.06 and its Current Ratio is at 13.06. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on March 11, 2024, initiated with a Overweight rating and assigned the stock a target price of $43.
On January 05, 2024, BofA Securities Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $31 to $34.
On January 04, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $41.Wedbush initiated its Outperform rating on January 04, 2024, with a $41 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 12 ’24 when Horn Margaret A sold 7,936 shares for $34.07 per share. The transaction valued at 270,345 led to the insider holds 142,467 shares of the business.
Horn Margaret A sold 15,735 shares of RVMD for $535,306 on Mar 11 ’24. The Chief Operating Officer now owns 142,467 shares after completing the transaction at $34.02 per share. On Jan 22 ’24, another insider, Cislini Jeff, who serves as the General Counsel of the company, sold 1,500 shares for $27.00 each. As a result, the insider received 40,500 and left with 36,126 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RVMD now has a Market Capitalization of 5.10B and an Enterprise Value of 3.33B. For the stock, the TTM Price-to-Sale (P/S) ratio is 438.04 while its Price-to-Book (P/B) ratio in mrq is 2.78. Its current Enterprise Value per Revenue stands at 287.61 whereas that against EBITDA is -7.74.
Stock Price History:
The Beta on a monthly basis for RVMD is 1.53, which has changed by 47.37% over the last 52 weeks, in comparison to a change of 31.54% over the same period for the S&P500. Over the past 52 weeks, RVMD has reached a high of $35.60, while it has fallen to a 52-week low of $15.44. The 50-Day Moving Average of the stock is 29.53, while the 200-Day Moving Average is calculated to be 27.43.
Shares Statistics:
It appears that RVMD traded 1.44M shares on average per day over the past three months and 2.21M shares per day over the past ten days. A total of 164.67M shares are outstanding, with a floating share count of 136.39M. Insiders hold about 17.18% of the company’s shares, while institutions hold 78.98% stake in the company. Shares short for RVMD as of Feb 29, 2024 were 17.15M with a Short Ratio of 11.90, compared to 16.95M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 10.41% and a Short% of Float of 10.81%.
Earnings Estimates
As of right now, 10 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.74 for the current quarter, with a high estimate of -$0.67 and a low estimate of -$0.85, while EPS last year was -$0.72. The consensus estimate for the next quarter is -$0.77, with high estimates of -$0.7 and low estimates of -$0.86.
Analysts are recommending an EPS of between -$2.99 and -$3.53 for the fiscal current year, implying an average EPS of -$3.18. EPS for the following year is -$3.47, with 10 analysts recommending between -$2.85 and -$4.02.
